key: cord-0969232-ulzpp0rx authors: Parai, Debaprasad; Dash, Girish Chandra; Choudhary, Hari Ram; Peter, Annalisha; Rout, Usha Kiran; Nanda, Rashmi Ranjan; Kshatri, Jaya Singh; Kanungo, Srikanta; Pati, Sanghamitra; Bhattacharya, Debdutta title: Diagnostic accuracy comparison of three fully automated chemiluminescent immunoassay platforms for the detection of SARS-CoV-2 antibodies date: 2021-03-05 journal: J Virol Methods DOI: 10.1016/j.jviromet.2021.114121 sha: 364a320a37f8a67847c24c643752bea0c045d09d doc_id: 969232 cord_uid: ulzpp0rx BACKGROUND: Serological test is an essential surveillance tool to track down the extensiveness of SARS-CoV-2 transmission and subsequently to move out from the enforced lockdown stage. OBJECTIVE: The study measures the diagnostic accuracy of three popular chemiluminescent immunoassay (CLIA) based automated platforms for the detection of anti-SARS-CoV-2 antibodies and compares their agreements. STUDY DESIGN: Serum samples of 594 COVID-19 positive patients and 100 samples from pre-COVID cases were tested by three CLIA based automated platforms: Abbott architect i2000SR, Roche cobas e411 and Yhlo iFlash 1800 and their diagnostic accuracy were compared by the area under the curves (AUC) value obtained from receiver operator characteristic (ROC) curves. Cohen’s kappa statistic and McNemar’s test were used to interpret the agreement between the platforms. RESULTS: All three platforms showed high specificity as claimed by the manufacturer. Sensitivity was calculated as 64.48% (58.67-70.3) for Abbott, 80.48% (76.62-84.34) for Roche and 76.94% (72.65-81.23) for Yhlo. AUC was maximum for Roche (0.929). The Cohen’s kappa value was determined in between 0.69-0.89 as the inter-rater agreements. CONCLUSION: The overall statistical analysis demonstrated cobas e411 as the diagnostically most accurate platform among the three. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. reaction (qRT-PCR) is the gold standard for molecular diagnosis of SARS-CoV-2 detection. However, sometimes it fails to demonstrate the complete picture of the viral transmission through communities (Winichakoon et al., 2020; Wu et al., 2020) . Hence, the serological test or antibody test is believed to be another important diagnostic tool along with the swab test. This test detects anti-SARS-CoV-2 immunoglobulins which are usually formed in the patient's body at the earliest by 1 week, and on average within 2-3 weeks from the infection onset. Antibody tests are a useful surveillance tool to track seroprevalence, assess the current immune status of a certain community, and may also be useful for decisions on lockdown entry-exit strategies (Fernández-Barat et al., 2020; Randolph and Barreiro, 2020) . Currently, there are several serological assays available in the market for the detection of anti-SARS-CoV-2 antibodies, mainly based on enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay (CLIA), or qualitative point-of-care tests (POCT) (WHO, 2020). The automated machines based on CLIA technology has a high throughput potential for the detection of anti-SARS-CoV-2 antibodies with high sensitivity and specificity (Bastos et al., 2020) . In this study, we compared three such CLIA-based analysers: ARCHITECT i2000SR (Abbott Laboratories, Chicago, USA), Cobas e411 (Roche Diagnostics GmbH, Mannheim, Germany) and iFlash 1800 (Shenzhen Yhlo Biotech Co. Ltd., Shenzhen, China) to detect their diagnostic accuracy and to identify the accurate one. Serum samples were collected from recovered COVID-19 patients after 4 weeks and not more than 8 weeks from the first qRT-PCR confirmation of SARS-CoV-2 infection. Oropharyngeal and nasopharyngeal swab specimens from all the suspected patients were tested and confirmed only after positive qRT-PCR results. Signed Informed consent was obtained from each individual before J o u r n a l P r e -p r o o f 5 their enrollment in the study. A total of 594 positive cases were chosen for this study between 23 rd July 2020 and 14 th September 2020. A total of 100 serum samples collected during the pre-COVID period (August 2019) and stored at -20°C in RMRC, Bhubaneswar repository were used as control. Repeated freeze-thawing were avoided. The study was approved by the Institutional Ethics Committee. ARCHITECT i2000SR platform used chemiluminescent microparticle immunoassay (CMIA) technology for the detection of immunoglobulin class G (IgG) antibodies against the nucleocapsid protein of SARS-CoV-2 from human sera. The second automated machine Cobas e411 was based on electrochemiluminescence (ECL) technology to detect total antibodies against nucleocapsid of SARS-CoV-2. The third one, iFlash 1800 was a paramagnetic particle linked chemiluminescent immunoassay (CLIA) technology to determine the IgG antibodies against SARS-CoV-2 nucleocapsid and spike protein. For details, see the supplementary file. Descriptive statistical analyses were performed by SPSS software (IBM SPSS Statistics for Windows, version 24.0, Armonk, NY). The agreement between the automated platforms was measured by Cohen's kappa (ĸ) statistic. McNemar's test was used to determine the significance of difference out of the three automated chemiluminescent immunoassay platforms. Specificity, sensitivity, negative predictive value (NPV) and positive predictive value (PPV) were calculated for each assay. The area under the curves (AUC) was compared from the receiver operator characteristic (ROC) curves of the three different platforms. p-value <0.05 was considered as statistically significant. J o u r n a l P r e -p r o o f 6 A total of 594 samples from recovered COVID-19 patients and 100 pre-COVID serum samples were analysed in all three CLIA platforms. In most of the convalescent COVID-19 patients, positive titres of anti-SARS-CoV-2 antibodies were observed for all three assay platforms (Fig. 1) . Among the 594 confirmed COVID cases, 378 sera samples (63.63%) were tested as reactive, whereas, 109 samples (18.35%) showed non-reactivity or negative across all three platforms. The calculated specificity and sensitivity of those anti-SARS-CoV-2 detecting automated platforms were described in Table S1 . Abbott showed a specificity of 99% (95% confidence interval Table S1 ). The ROC performance curves (Fig. 1) showed that Roche platform had the highest AUC value of 0.929 (95% CI: 0.910 -0.948). Architect i2000SR gave AUC value of 0.863 (95% CI: 0.836 -0.889) and for iFlash 1800, it was found to be 0.897 (95% CI: 0.875 -0.920). Inter-rater agreements among Roche, Abbott and Yhlo were calculated and described in Table 1 . The best agreement was found between Roche and Yhlo and the least was detected in Roche vs Abbott. McNemar's test showed significant differences in detection rate among these three similar assay platforms. Routine antibody tests are necessary to identify the community transmission, to determine the herd immunity status and to screen potential convalescent plasma donors (Goudsmit 2020; Zhao et al., 2020) . To our best knowledge, the concordance of these three popular automated chemiluminescent assay platforms is evaluated for the first time in this study. The 18.35% of nonreactive results revealed a majority of COVID-19 recovered patients were unable to produce detectable titre of antibodies. Both Roche and Yhlo platform were found to have 100% specificity, which is more than the manufacturer claimed value. In terms of sensitivity, Roche insert showed the highest sensitivity for anti-SARS-CoV-2 antibodies including IgG compared to both Abbott and Yhlo. A study by Perkmann et al. showed a higher sensitivity for Abbott (84.6%) and Roche (89.2%) platforms although that might be because of the low number of recruited COVID-19 patients (n=65) (Perkmann et al., 2020) . Similarly, another study with iFlash SARS-CoV-2 IgG measured sensitivity of 76.7% with 61 positive sera which are the same (76.9%) as our result and also corroborated our study with a higher sample size (Infantino et al., 2020) . The AUC values represented the diagnostic accuracy of all three platforms, and Roche gave the highest value of 0.929 at 95% CI. Inter-rater agreement among those platforms was statistically good and found to be the highest between Roche and Yhlo. As per our study, Roche Cobas e411 automated chemiluminescent platform gave the best diagnostic accuracy. The other two platforms weren't far behind as determined by the percent agreement from ĸ analysis. Elecsys Anti-SARS-CoV-2 assay is based on the determination of total antibody against nucleocapsid of SAR-CoV-2 whereas iFlash SARS-CoV-2 IgG assay detected IgG against both nucleocapsid and spike proteins. Both the inserts had an agreement of 95.2% even though they targeted different antigens. In conclusion, the detection of anti-SARS-CoV-2 antibodies is significantly different across the three different automated chemiluminescent assay platforms. Roche Cobas e411 automated Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis The value of serology testing to manage SARS-CoV-2 infections The paramount importance of serological surveys of SARS-CoV-2 infection and immunity Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity Herd Immunity: Understanding COVID-19 Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19 Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief A new coronavirus associated with human respiratory disease in China Antibody responses to SARS-CoV-2 in patients of The authors gratefully acknowledge all the healthcare workers for their tireless dedication at each level to fight COVID-19. The authors are thankful to the Indian Council of Medical Research, New Delhi for providing financial grants for this study.J o u r n a l P r e -p r o o f